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Background: Pentameric ligand-gated ion channels are modulated by general anesthetics.
Results: The crystal structure of ELIC in complex with bromoform reveals anesthetic binding in the channel pore and in novel
sites in the transmembrane and extracellular domain.
Conclusion: General anesthetics allosterically modulate channel function via multisite binding.
Significance:Our data reveal detailed insight into multisite recognition of general anesthetics at the structural level.
Pentameric ligand-gated ion channels (pLGICs), such as nic-
otinic acetylcholine, glycine, -aminobutyric acid GABAA/C
receptors, and theGloeobacter violaceus ligand-gated ion chan-
nel (GLIC), are receptors that contain multiple allosteric bind-
ing sites for a variety of therapeutics, including general anes-
thetics.Here,we report the x-ray crystal structure of theErwinia
chrysanthemi ligand-gated ion channel (ELIC) in complexwith a
derivative of chloroform, which reveals important features of
anesthetic recognition, involving multiple binding at three dif-
ferent sites. One site is located in the channel pore and equates
with a noncompetitive inhibitor site found in many pLGICs. A
second transmembrane site is novel and is located in the lower
part of the transmembrane domain, at an interface formed
between adjacent subunits. A third site is also novel and is
located in the extracellular domain in a hydrophobic pocket
between the7–10 strands. Together, these results extend our
understanding of pLGICmodulation and reveal several specific
binding interactions that may contribute tomodulator recogni-
tion, further substantiating a multisite model of allosteric mod-
ulation in this family of ion channels.
General anesthetics, including alcohols and inhalational sur-
gical agents, inhibit nerve signaling by interacting with proteins
in the brain and spinal cord (1). One of the primary classes of
neurological proteins modulated by general anesthetics is that
of pentameric ligand-gated ion channels (pLGICs),5 which
include ionotropic receptors for acetylcholine (ACh), Gly, and
-aminobutyric acid (GABA) (2). Cation flux through nicotinic
acetylcholine receptors (nAChRs) is generally excitatory and is
inhibited by general anesthetics; conversely, chloride flux
through Gly receptors (GlyRs) and GABA type A receptors
(GABAARs) generally inhibits neuronal signaling, and many of
these proteins are functionally enhanced by general anesthetics
(3). An interesting exception to this rule is the  subtype of
GABAAR (often referred to as GABACR), which conducts chlo-
ride but is inhibited by alcohols and anesthetics (4).
Several specific protein sites in pLGICs have been implicated
in general anesthetic binding. Channels in this family are pen-
tamers of identical or similar subunits, each of which contrib-
utes to a ligand binding extracellular domain, a pore-forming
transmembrane domain, and a variable cytoplasmic domain
(5).Mutagenesis (6), labeling (7), andmolecular dynamics stud-
ies (8) of nAChRs have implicated the transmembrane domain
in nAChR inhibition, possibly via obstruction of the channel
pore. Conversely, a range of chimera andmutagenesis studies of
GlyRs and GABAARs has implicated both intrasubunit and
intersubunit transmembrane sites (9), as well as locations in the
ligand binding (10) and intracellular (11) domains, in channel
potentiation by alcohols and other general anesthetics. The
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range of implicated sites, as well as relatively high (high M to
lowmM (12)) concentrations required to induce anesthesia, and
the lack of distinctive pharmacophores for most of these agents
(13) have led to the proposal that anesthetics may modulate
channel function through simultaneous interactions with mul-
tiple distinct sites on any given receptor (2).
Recent crystal structures of homologs from bacteria and
nematodes have revealed critical details of pLGIC structure.
The ELIC structure is thought to present a nonconducting con-
formation, possibly corresponding to the closed state, whereas
theGloeobacter violaceus ligand-gated ion channel (GLIC) and
glutamate-activated chloride channel (GluCl) structures repre-
sent a conducting conformation, possibly corresponding to the
open state (14, 15). GLIC forms cation-selective channels that
are activated by low pH and modulated by most alcohols (16)
and other general anesthetics (17) in a manner similar to
nAChRs andGABACRs; furthermore, its structurewas recently
determined in complex with the general anesthetics desflurane
and propofol (18). Surprisingly, although general anesthetics
are presumed to stabilize the closed or desensitized state(s) of a
cation-selective ion channel (19), the known anesthetic-bound
GLIC structures are associated with a presumed open state,
superimposable with the modulator-free form solved in the
presence of ligand (protons) (20). Thus, the structural conse-
quences of binding modulators, particularly inhibitory agents
such as general anesthetics, remain unclear. In this work, we
sought to extend the observation of general anesthetic modu-
lation of pLGICs to the model system of ELIC, which is a
recently discovered GABA-activated bacterial pLGIC (21–24).
EXPERIMENTAL PROCEDURES
Protein Expression and Crystallization—ELIC was expressed
and purified as described previously, but with minor modifica-
tions (21). In brief, ELIC was cloned into pET-11a expressed in
the C43 Escherichia coli strain as an N-terminal fusion to malt-
ose-binding protein. Membranes were solubilized with 2%
Anagrade n-undecyl--D-maltoside (Anatrace), and the solubi-
lized fraction was incubated with amylose resin (New England
Biolabs). Affinity-bound protein was cleaved off with 3CV pro-
tease and further purified using size exclusion chromatography
on a Superdex 200 10/300 GL (GE Healthcare). The running
buffer was composed of 10 mM sodium phosphate, pH 8.0, 150
mM NaCl, and 0.15% n-undecyl--D-maltoside. Concentrated
protein (10 mg/ml) was supplemented with E. coli lipids
(Avanti Polar Lipids), and co-crystallization of ELIC with bro-
moform and bromoethanol (Sigma-Aldrich) was performed by
sitting drop vapor diffusion at 4 °C. The crystallization buffer
was composed of 200 mM ammonium sulfate, 50 mM N-(2-
Acetamido)iminodiacetic acid (ADA), pH 6.5, and 9–12% PEG
4000. Crystals of ELIC in complex with bromoform were
obtained at bromoform concentrations from 1 to 10 mM. Crys-
tals were harvested after adding 30% glycerol as a cryopro-
tectant to the mother liquor. Crystals were cryo-cooled by
immersion in liquid nitrogen. Crystals of ELIC in complex with
bromoethanol did not diffract to sufficiently high resolution to
allow structure determination.
Structure Determination and Refinement—Adiffraction data
set to a resolution of 3.65 Å was used for structure determina-
tion and refinement (crystallographic statistics are shown in
Table 1). Data integration was done in XDS, and scaling was
done in SCALA. Model building and refinement were carried
out by iterative cycles of manual rebuilding in COOT and
refinement in PHENIX, using one Translation Libration Screw
(TLS) body per subunit and five-fold Non-Crystallographic
Symmetry (NCS) restraints. Anomalous difference density
mapswere calculated using reflections between 25 and 5Å. The
clearest anomalous peaks could be observed when data sets
from three different crystals were merged to calculate anoma-
lous maps (see statistics for the merged data set in Table 1).
TABLE 1
Data statistics and refinement
SLS, Swiss Light Source; r.m.s.d., root mean square deviation.
Data set 1
(crystal one)
Data set 2
(merged from three crystals)
Crystallographic statistics
Beamline X06A (SLS) X06A (SLS)
Date of collection September 13, 2011 September 13, 2011
Wavelength (Å) 0.9193 0.9193
Space group P21 P21
a, b, c (Å) 105.11, 266.25, 110.75 105.63, 266.33, 110.97
 (°) 109.78 108.63
Resolution limits (Å) 44.08–3.65 (3.85–3.65) 25.00–5.00 (5.27–5.00)
Rmerge (%) 10.6 (67.6) 19.2 (33.3)
Rmeas 12.4 (78.9) 20.7 (35.8)
I/ 9.5 (2.1) 12.1 (6.6)
Multiplicity 3.8 (3.7) 11.3 (11.5)
Completeness (%) 98.9 (97.0) 99.2 (100.0)
Total number of reflections 237,239 (33495) 282,159 (42154)
Number unique reflections 62,852 (8988) 24,931 (3680)
Anomalous completeness 94.6 (92.6) 99.2 (100.0)
Anomalous multiplicity 1.9 (1.9) 5.6 (5.6)
Refinement and model statistics
Number of residues in ASU 3220
Number of atoms in ASU 52,170
Rwork (%) 22.87
Rfree (%) 26.39
r.m.s.d. bond distance (Å) 0.008
r.m.s.d. bond angle (°) 1.335
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Because bromoform is a relatively symmetric and small mole-
cule, we were not able to assign a unique binding pose at the
present resolution limit, and therefore, we built a single bro-
mine atom into each anomalous electron density peak. Model
validation was done using MOLPROBITY, and all figures were
prepared using PyMOL. The analysis of pore dimensions was
carried out using HOLE (25).
Mutagenesis and Two-electrode Voltage Clamp Recordings—
For expression in Xenopus laevis oocytes, cDNAs encoding
ELIC and human 1 GlyR were subcloned into pGEM-HE (26).
Allmutant receptors were created using aQuikChangemethod
(Stratagene) and verified by sequencing (Agowa). The plasmids
were linearized with NheI, and capped cRNA was synthesized
using the T7 mMESSAGE-mMACHINE transcription kit
(Ambion). Stage V-VI oocytes, prepared as described previ-
ously (23), were freshly harvested from the ovarian lobes of
anesthetized frogs and subsequently injected with 30 nl of
cRNA (100 ng/nl). The oocyte incubation solution contained
(in mM): 96 NaCl, 2 KCl, 1.8 CaCl2, 2 MgCl2, and 5 HEPES (pH
7.4), supplemented with 50 mg/liter gentamicin sulfate.
Whole-cell currents from oocytes were recorded 1–2 days
after injection using the two-electrode voltage clamp tech-
nique. For ELIC recordings, all electrophysiological experi-
ments were conducted at a constant temperature (18 °C) using
anAxoclamp 900A amplifier (MolecularDevices) controlled by
a pClamp 10.2 data acquisition system (Molecular Devices).
Data were sampled at 100 Hz and low pass-filtered at 10 Hz
using a four-pole Bessel filter. Voltage and current electrodes
were backfilled with 3 M KCl, and their resistances were kept as
low as possible (1 megaohms). Oocytes were clamped at60
mV throughout all recordings. The bath perfusion solution
contained (in mM): 96 NaCl, 2 KCl, 1.8 CaCl2, 1 MgCl2, 5
HEPES (pH 7.4). Current responses were separated by 180-s
ligand-free intervals to avoid effects of desensitization. For con-
structing concentration-response curves, current responses
were evoked by co-applications of GABA with modulator in
between applications of GABA alone. To allow equilibration in
the bath and to monitor direct effects on receptor function,
co-applications of GABA with modulator were preceded by a
30-s preapplication of modulator alone. Solutions containing
bromoform were prepared from a 1 M stock solution in
dimethyl sulfoxide (DMSO) appropriately diluted into bath
perfusion solution. The modulation was quantified by compar-
ing current amplitudes in the presence and absence of modula-
tor. Concentration-inhibition curves were fitted according to
the Hill equation: y 100/(1 (IC50/[modulator])nH), where y
is normalized current, IC50 is the concentration of modulator
producing 50% inhibition, [modulator] is the modulator con-
centration, and nH is the Hill coefficient. Data analysis was car-
ried out with Clampfit 10.2 (Molecular Devices) and Origin 7.0
(OriginLab).
For 1 GlyR recordings, we used a HiClamp apparatus
(MultiChannel Systems, Reutlingen, Germany). The mem-
brane potential of oocytes was clamped at a value of 80 mV,
and currents evoked by Gly or compounds were recorded with
a sampling frequency of 100Hz. All recordings were performed
at 18 °C, and cells were superfused with OR2 medium contain-
ing (in mM): 82.5 NaCl, 2.5 KCl, 1.8 CaCl2, 1 MgCl2, and 5
HEPES (pH 7.4). Concentration-activation curves were fitted
according to the Hill equation: y Imax/[1 (EC50/[agonist])nH],
where y is the normalized current amplitude, Imax is themax-
imal efficacy, EC50 is the agonist concentration at half-max-
imal efficacy, [agonist] is the agonist concentration, and nH
is the Hill coefficient. Curve fitting was carried out using the
least squares method in MATLAB. All numerical data are pre-
sented as means  S.E. Statistical differences were assessed
using a Student’s t test.
Quenching of Intrinsic TryptophanFluorescence inDetergent-
solubilized ELIC—Intrinsic tryptophan fluorescence quench-
ing experiments were performed under equilibrium conditions
using a FlexStation 3 microplate reader (Molecular Devices).
295 nmwas used as the excitationwavelength, and fluorescence
emission spectra were recorded from 320 to 370 nm. The fluo-
rescence peak maximum for ELIC was near 340 nm, which was
used as the emission wavelength for calculating quenching
plots. The fluorescence quenching experiments were per-
formed in the presence of 0–20mMbromoform, and potassium
bromide was used to evaluate nonspecific quenching. The
quenched fluorescence was plotted as F/F0, where F0 and F are
the fluorescence intensity in the absence and presence of bro-
moform, respectively.
RESULTS
Functional Effects of General Anesthetics on ELIC—To inves-
tigate whether ELIC is a useful model to study channel modu-
lation by general anesthetics, we expressed ELIC in Xenopus
oocytes and characterized the effects of various anesthetics,
including chloroform, propofol, etomidate, and alcohols. To
facilitate structural studies, we also tested the bromo analogs
bromoform (Fig. 1a) and bromoethanol. Using the two-elec-
trode voltage clamp technique, we applied the ELIC agonist
GABA and compared current amplitudes in the absence and
presence of anesthetics. We observed that ELIC is inhibited by
micromolar concentrations of bromoform/chloroform and
millimolar concentrations of alcohols (Fig. 1b). From concen-
tration-inhibition curves, we calculated IC50 values of 125 10
M for bromoform (n  4–10), 162  26 M for chloroform
(n 2–3), 125 5mM for ethanol (n 3–4), and 72 5 formM
bromoethanol (n  3–9) (Fig. 1c). These results demonstrate
that ELIC has pharmacological properties that are different
from the related bacterial homolog GLIC and the more distant
human pLGICs. For example, chloroform potentiates agonist-
activated responses at GlyR (27) and GABAAR (28–30),
whereas chloroform inhibits ELIC. In addition, methanol and
ethanol potentiate agonist responses of GLIC (16) and human
pLGICs (31, 32), whereas ethanol and bromoethanol inhibit
ELIC. Despite these differences between ELIC and human
pLGICs, our data demonstrate that certain anesthetics, includ-
ing bromoform and chloroform, bind with IC50 values compa-
rable with human pLGICs and suggest that ELIC is a potentially
suitable model for structural studies.
X-ray Crystal Structure of ELIC in Complex with Bromoform—
We determined the crystal structure of ELIC in complex with
bromoform, a chloroform analog, to take advantage of the
anomalous diffraction signal generated by bromine atoms and
facilitate the identification of bromoform binding sites in ELIC.
Multisite Anesthetic Binding Revealed in ELIC Structure
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FIGURE 1.Modulationof ELICbybromoform. a, chemical formulas of chloroformandbromoform. b, ELIC current traceswere evokedby application of 5mM
GABA in the absence and presence of 200 M bromoform or 100 mM bromoethanol. c, concentration-inhibition curves from the experiments shown in
panel b. Squares are data for bromoform, and circles are data for bromoethanol (mean  S.E.). Each data point represents the average of 3–10
experiments.
FIGURE 2. X-ray crystal structure of ELIC in complex with bromoform. a, side view of ELIC in graphic representation and overlay with anomalous
electron density, shown asmagenta mesh at a contour level of 4. Each subunit of the pentamer is shown in a different color. Anomalous densities can
be observed in the extracellular domain, transmembrane domain, and channel pore. b and c, extracellular and intracellular view of ELIC along the
five-fold symmetry axis. The pore site is lined by the M2-helices of each of the five subunits. The transmembrane site is formed at the interface between
two subunits, involving the M1- and M4-helix of one subunit and the M3-helix of the neighboring subunit. Bromoform molecules are represented as a
single magenta sphere. d, comparison of the bromoform binding site in the closed channel pore of ELIC (left) and bromo-lidocaine binding site in the
open channel pore of GLIC (right). Bromoform and bromo-lidocaine occupy overlapping binding sites, which are located in the hydrophobic part of the
ion conduction pathway (hydrophobic residues are colored in yellow, hydrophilic residues are in green, and charged residues are in red). e, mutagenesis
experiments in ELIC demonstrate that the inhibitory effect of 200 M bromoform is almost completely eliminated in L9S and strongly reduced in F16S
mutants. The inhibitory effect of bromoform was tested at an EC20 concentration of GABA, which was 0.5 mM for L9S and 3 mM for wild type and F16S.
Error bars represent mean S.E. from 3–5 different experiments. Asterisks indicate significant difference from wild type (p 0.05).
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Fig. 2, a–c, show a graphic representation of ELIC and an over-
lay with anomalous electron density shown as a magenta mesh.
We clearly observe anomalous density at three different loca-
tions in ELIC, namely in the channel pore, at a site in the extra-
cellular domain, and at a transmembrane site, which is at the
interface between two neighboring subunits.
The strongest anomalous density can be observed in themid-
dle of the channel pore at a position near 13Aof the pore-lining
M2-helix (Fig. 2d, left), corresponding to the hydrophobic part
of the channel pore (Fig. 2d, hydrophobic residues are shown in
yellow, hydrophilic residues are shown in green, and charged
residues are shown in red). This indicates that a bromoform
molecule is bound close to the 13A side chain and apparently
stabilized between the bulkier 9L and 16F residues. This bind-
ing site overlaps with the recently described site for bromo-
lidocaine in the open GLIC structure (Fig. 2d, right) (33), which
likely represents the binding site for extensively studied non-
competitive inhibitors such as tricyclic antidepressants, chlor-
promazine, lidocaine, and quinacrine (34–38). To investigate
the functional importance of this hydrophobic site, wemutated
9L and 16F in ELIC to the hydrophilic Ser residue and com-
pared the inhibitory effects of bromoform with wild type ELIC
(Fig. 2e). We observed that the inhibition of ELIC by 200 M
bromoform is almost completely eliminated in the 9S mutant
(no further inhibition could be observed at bromoform concen-
trations up to 2 mM) and significantly reduced in the 16S
mutant. This result indicates that the hydrophobic region of the
channel pore between 9 and 16 functionally contributes to the
inhibitory effects of bromoform on ELIC and forms a possible
binding site for general anesthetics.
Comparison of the bromoform-bound complex of ELICwith
the previously published apoELIC structure (ProteinData Bank
(PDB) code 2vl0 (21)) reveals that the pore-forming M2-helix
undergoes a subtle conformational change upon binding of
bromoform (Fig. 3a). This becomes especially clear upon com-
parison of the pore radius calculated for the two structures (Fig.
3b). The inward movement of the M2-helices causes the chan-
nel pore to adopt a more closed conformation than in the apo
structure, particularly in the upper half (20 to 13) of the pore.
We calculated that the pore radius in the bromoform-bound
structure is reduced to 1.2Å at 20, 1.1 Å at 16, and 2.5Å at 13,
compared with 1.7, 1.5, and 3.3 Å in apoELIC (Fig. 3b). This
conformational change in theM2-helices likely enables optimal
hydrophobic interactions with the bromoformmolecule bound
near 13A.
In the extracellular domain, we find anomalous density
behind the 7–10 strands where a hydrophobic site is formed
by residues Leu-128 and Ile-195 (Fig. 2b). In the lower part of
the transmembrane domain, we find anomalous density in a
pre-existing pocket formed at the protein-lipid interface,
between the M1- and M4-helices of one subunit and the
M3-helix of a neighboring subunit (Fig. 2c). This intersubunit
bromoform site in ELIC is different from the previously identi-
fied binding site for propofol and desflurane in GLIC (18),
which is located farther up the transmembrane domain at an
intrasubunit pocket (Fig. 4a). The intersubunit bromoform site
is formed at five pre-existing cavities in the ELIC pentamer (Fig.
4, b and c). Such cavities are absent in the GLIC and Caenorh-
abditis elegansGluCl structures (14), where the protein surface
forms a lipid-exposed groove, rather than a pocket. Detailed
analysis of the amino acid side chains contributing to the trans-
membrane pocket shows that this site is lined by several aro-
matic residues (Fig. 4d, Trp-221 and Trp-225 in M1 and Phe-
275 in M3) as well as several hydrophobic residues (Ala-218 in
M1; Ile-278, Leu-279, and Ile-282 inM3; and Leu-303 and Pro-
306 in M4).
To further probe the importance of this novel intersubunit
transmembrane site, we took advantage of the presence of two
tryptophan residues (Trp-221 and Trp-225 in ELIC) and inves-
tigated the possible quenching of intrinsic tryptophan fluores-
cence in the presence of bromoform. We observe that increas-
ing concentrations of bromoform progressively decrease
intrinsic tryptophan fluorescence of detergent-solubilized
ELIC (Fig. 5) and that this effect is strongly reduced in the
W221YW225Y mutant. These data demonstrate that the
intersubunit cleft inside the membrane forms a binding site for
bromoform. Further experiments in oocytes supported these
data; at an EC20 GABA concentration, L9S receptors were not
significantly inhibited by bromoform (described above), but
L9SF275A and L9SW225Amutant receptors showed sig-
nificant inhibition, with EC20 currents reducing to 78 4 (n
3) and 81 6% (n 3), respectively, in the presence of 200 M
bromoform.
Using an alignment of ELIC with sequences of the related
GLIC channel and human pLGICs, we found that amino acid
residues forming the transmembrane bromoform site in ELIC
are highly conserved inGLIC and anionic pLGICs (GABAA/CRs
FIGURE 3. Bromoform stabilizes the ELIC pore in a closed conformation.
a, ribbon representation of the pore-lining M2-helix in the apoELIC structure
(blue, PDB code 2vl0) and the bromoform-bound structure (red). The view is
along the five-fold symmetry axis lookingdownon the channel pore from the
extracellular domain. The dashed lines are distance measurements between
13AC atoms of different subunits. b, pore radius analysis for apoELIC (blue),
bromoform-bound ELIC (red), and GLIC, which likely corresponds to an open
pore conformation (PDB code 3eam).
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and GlyRs), but not in cationic family members (nAChRs and
5-HT3Rs) (Fig. 6). The high degree of residue conservation indi-
cates that the intersubunit pocket not only exists in ELIC, but
also is likely to exist in anionic pLGICs, where it potentially
could mediate functional effects in eukaryotic inhibitory
receptors.
Structure-guided Mutagenesis of Bromoform Interactions in
Human 1 Glycine Receptors—The aromatic residues forming
the intersubunit bromoform site are strongly conserved in an-
ionic pLGICs, but not in cationic pLGICs, which indicates that
this site may have a specific role in GABAA/CRs and GlyRs. To
investigate the possible functional contribution of this site to
the general anesthetic modulation of eukaryote receptors, we
chose the human 1 GlyR as a model receptor for mutagenesis
studies. The1GlyR is a homopentameric receptor, which sim-
plifies interpretation of mutagenesis experiments, and its mod-
ulation by general anesthetics, including chloroform, has been
studied extensively (27, 39–42). We mutated the homologous
residues Phe-295 and Tyr-301 in the human 1 GlyR, which
correspond to Phe-275 and Ile-282 in the M3-helix of ELIC
(Fig. 7a).We chose these residues because they are strictly con-
served aromatic residues in anionic, but not in cationic,
eukaryote pLGICs (Fig. 6). Using two-electrode voltage clamp
recordings from Xenopus oocytes, we measured ligand-acti-
vated currents for a range of glycine concentrations (from 3M
to 3 mM, Fig. 7b) and compared the functional effects of wild
type with F295A and Y301A receptors in the absence and pres-
ence of 200 M bromoform.
From the concentration-activation curve for wild type recep-
tors (Fig. 7c), we calculated an EC50 value of 98  4 M and a
Hill coefficient (nH) of 3.8 0.2 (n 5), which is in agreement
with other studies (43). When compared with wild type recep-
tors, we observe that the concentration-activation curve of
F295A receptors is significantly shifted to the left (Fig. 7c) with
an EC50 value of 22 1M and nH of 3.1 0.2 (n 7, p 0.05).
In contrast, the concentration-activation curve of Y301A
receptors is shifted to the right (Fig. 7c) with an EC50 value of
688  35 M and nH of 2.25  0.09 (n  5). These results are
indicative of an important role of these residues in channel
gating as the F295A mutation appears to lower the energy bar-
rier for glycine-induced channel opening, whereas the Y301A
mutation is compatible with a glycine-induced increase of the
energy barrier for channel opening.
In the presence of bromoform (Fig. 7d), we observe for wild
type and F295A receptors a small but significant increase in
FIGURE 4.Molecular recognition of bromoform at an intersubunit trans-
membrane site. a and b, Comparison of the propofol binding site in GLIC (a)
and thebromoformbinding site of ELIC (b) in a surface representation. Propo-
fol binds in an intrasubunit pocket in the upper half of the transmembrane
domain. Bromoform binds in an intersubunit pocket farther down the trans-
membrane domain. The transmembrane domains of two neighboring sub-
units are shown in orange and blue. The propofol andbromoformpockets are
highlighted in yellow. The extracellular domain is shown in white. The inset
shows a more detailed view of the intersubunit transmembrane site. The
magenta mesh represents anomalous electron density contoured at 4.
c, cross-section through a surface representation of ELIC. The intersubunit
bromoform site is formed at a pre-existing cavity, which is occupied by a
bromoformmolecule (single bromine atoms are shown asmagenta spheres)
in all five sites. d, detailed view of the amino acid residues in ELIC that form
the intersubunit bromoform site (highlighted in yellow). The site is formed at
the interface betweenM1 andM4 of one subunit (blue) andM3 of the neigh-
boring subunit (orange).
FIGURE 5.Quenching of intrinsic tryptophan fluorescence in ELIC by bro-
moform. Increasing concentrationsof bromoformcausequenchingof intrin-
sic fluorescence in ELIC. This effect is strongly reduced in the double mutant
W221Y/W225Y. Each data point is the average of 3 experiments. Error bars
indicate S.E.
FIGURE 6. Conservation of bromoform binding residues at a transmem-
brane intersubunit site in pLGICs. Alignment of ELIC, GLIC, and selected
sequences of humanGlyR, GABAA/CR, nAChR, and 5-HT3Rs is shown.Numbers
at the top of the alignment correspond to ELIC residues, and numbers at the
bottom correspond to1GlyR residues. Residues are colored in shadesofblue
using an identity threshold of 50%. Yellow residues correspond to the high-
lighted residues in the intersubunit bromoform site in ELIC (Fig. 3d). Aromatic
residues at these positions as well as Pro-307 are strongly conserved in GlyR
and GABAA/CR, but not in nAChR and 5-HT3Rs. The dashed line separates
inhibitory (top) from excitatory (bottom) receptors.
Multisite Anesthetic Binding Revealed in ELIC Structure
8360 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288•NUMBER 12•MARCH 22, 2013
 at SK
ID
M
O
RE CO
LLEG
E on A
pril 11, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
EC50 values (112 6M, n 5 for wild type, p 0.05 and 26
2M, n 7 for F295A receptors, p 0.05). In addition, bromo-
form reduced the maximal current amplitude at saturating gly-
cine concentrations (Imax) to 76.6 0.9% (n 5) for wild type
and 76 6% (n 7) for F295A receptors, respectively. Bromo-
form also reduces the slope of the concentration-activation
curve (nH) to 2.8 0.1 for wild type (n 5, p 0.05) and 2.2
0.1 (n  7, p  0.05) for F295A receptors. At low glycine con-
centrations, however, bromoform caused a significant potenti-
ation of F295A receptors when compared with wild type recep-
FIGURE 7. Mutagenesis of the intersubunit bromoform binding site in the human 1 glycine receptor. a, graphic representation of the intersubunit
bromoform binding site in the transmembrane domain of ELIC. Interacting residues are shown in yellow sticks. The bromoformmolecule is shown as a single
magenta sphere. b, two-electrode voltage clamp recordings from oocytes expressing wild type 1 GlyRs, F295A, and Y301A mutants. Each current trace is
shown in a specific color to facilitate comparison of the range of glycine concentrations: 3 M (green), 10 M (red), 30 M (blue), 100 M (yellow), 300 M
(magenta), 1mM (cyan), and3mM (black). To reach saturation for Tyr-301 receptors,wealso applied10mM (orange). Eachoocytewasexposed to the same range
of glycine concentrations in the presence of 200 M bromoform (BrF). The insets for WT and F295A show a magnified view of traces obtained at low glycine
concentrations. The asterisk indicates potentiation by bromoform. c, concentration-activation curves for WT, F295A, and Y301A GlyRs in the absence of
bromoform.d–f, concentration-activation curves in the absence (gray line,BrF) andpresence (black line,BrF) of 200Mbromoform forWT (d), F295A (e), and
Y301A (f) receptors. Error bars in panels c–f indicate S.E.
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tors (Fig. 7b, inset, asterisk), indicating that this residue may
play a role in bromoformmodulation. The evidence is stronger,
however, for a role of Tyr-301 as the EC50 value of Y301A in the
presence of bromoform was increased to 1240  60 M (p 
0.05), with Imax being reduced to 64 6%. Low glycine concen-
trations (3–100 M, indicated with asterisk) again resulted in
bromoformpotentiation in Y301A receptors. Thus, as reported
previously for anesthetic effects in GABA receptors (4, 44),
changes caused by bromoform exposure can be diametrically
opposed and depend on agonist concentration. The interpreta-
tion of our data obtained from two-electrode voltage clamp
recordings onmutantGlyR is difficult because themacroscopic
effect on channel current likely depends on the action of bro-
moform at multiple binding sites, as suggested by the ELIC
crystal structure. In addition, it is possible that the mutations
either have direct effects on bromoform recognition or alterna-
tively, cause allosteric effects that indirectly alter channel mod-
ulation by bromoform. Despite these limitations, our results
support the hypothesis that the transmembrane binding site for
bromoform, observed in the ELIC crystal structure, is also pres-
ent in GlyRs asmutation of Phe-295 and Tyr-301 alters bromo-
form modulation.
DISCUSSION
Similar to nAChRs (45), GABACRs (4), and GLIC (16, 17),
ELIC exhibited inhibition by alcohols and other general anes-
thetics. These results are consistent with the expanding theme
of pLGIC sensitivity to general anesthetic modulation (2) and
support the relevance of ELIC as amodel for pLGIC function as
well as structure. Furthermore, consistent with evidence from
other pLGICs, ELIC bound the anesthetic derivative bromo-
form at multiple sites, including a transmembrane site at the
protein-lipid interface. The low affinity and therapeutic index
of inhalational anesthetics require caution in interpreting bind-
ing observed at high concentrations of modulators (1); how-
ever, some bromoform-bound ELIC crystals were grown with
as little as 1 mM of the agent, close to the EC50 both for inhibi-
tion of ELIC and for chloroform anesthesia in humans (12).
This similar potency, combinedwith the presence of equivalent
sites in other pLGICs, suggests that anesthetic inhibition of
ELIC and related channels arises from binding to one or more
of the sites we observe, and by extrapolation, anesthetic inhibi-
tion in related channels is due to their binding to the equivalent
sites in these proteins.
The strongest bromoform anomalous signal occupied a
pore-blocking site near the 13A residue in theM2-helix. These
data are consistent with high occupancy of bromoform,
although the occupancy was amplified by its position on the
five-fold noncrystallographic symmetry axis imposed to refine
the structure. Binding of inhibitors in the channel pore is con-
sistent with mutagenesis, labeling, and molecular dynamics
studies of nAChRs (6–8). The anesthetic position is also equiv-
alent to that observed in a recent co-crystal structure of GLIC
with the local anesthetic derivative bromo-lidocaine (33);
moreover, molecular dynamics studies of GLIC binding to the
volatile anesthetics isoflurane and propofol (46, 47) support
binding in the channel pore, in addition to other sites. Given the
steric occlusion to ion conductance that would result from
occupancy of the pore by an agent the size of bromoform, bind-
ing at this position seems likely to contribute to inhibition of
ELIC. This is confirmed by our mutagenesis study in ELIC,
which demonstrates that the pore mutants L9S and F16S dis-
play less inhibition by bromoform.
A previous study has revealed binding of isoflurane to an
otherwise dehydrated, presumed nonconducting state of the
GLIC pore (46). This work is consistent with the present struc-
ture, which shows bromoform binding to a presumed closed
state of the channel. Willenbring et al. (46) proposed that the
small, hydrophobic nature of most general anesthetics allows
them to pass the channel hydrophobic gate even in a conforma-
tion that is unable to pass water or ions. Anesthetics may, in
fact, preferentially bind to the closed state, which is better rep-
resented by the ELIC pore than the open state represented by
GLIC. The presence of detergent molecules bound in the pore
of the knownGLIC crystal structures (20) could prevent obser-
vation of anesthetics in equivalent sites in the known anesthetic
co-crystal structures (18).
A second bromoform site occupied the intersubunit cleft,
facing the membrane and close to the intracellular side in the
transmembrane domain. The general anesthetics halothane
and thiopental quenched tryptophan fluorescence in an equiv-
alent site in a recent study of GLIC (48). The intersubunit bind-
ing site is surrounded by hydrophobic aromatic residues that
are conserved in GlyRs and GABAARs, but not in nAChRs,
consistent with a subtype-specific role for this site in modula-
tion or in another critical aspect of channel gating. The mem-
brane-facing intersubunit interface also binds the allosteric
activator ivermectin in recent co-crystal structures with the
C. elegans glutamate-gated chloride channel (14), further sup-
porting a role for intersubunit binding in allosteric modulation
of channel function. A proximal intersubunit cavity, closer to
the extracellular side than the pocket observed here, has been
heavily implicated in anesthetic potentiation of GlyRs andmost
GABAARs (9). This “higher” intersubunit cavity was also
recently shown to mediate alcohol potentiation of the bacterial
channel GLIC (16). Blockage of this alternative intersubunit
site, for example by substituting isoleucine at the aligned resi-
dues Ser-270 in 1 and Ser-265 in 1 GABAAR subunits,
resulted in channel inhibition by ethanol and enflurane (49),
suggesting that potentiation via this site masked an indepen-
dent mechanism of inhibition, perhaps via one or more alter-
native binding sites.
Notably, the intrasubunit transmembrane binding site occu-
pied by desflurane and propofol in recent co-crystal structures
with GLIC (18) was not occupied by bromoform in our ELIC
co-crystal structure. This result may indicate differences in
bindingmodes for the two channel types; it may also reflect the
limitations of co-crystallization with a channel “locked” in a
particular functional state. The presumed preferential binding
of inhibitors to the closed state(s) of an ion channel (19) sup-
ports the relevance of the binding modes observed with the
closed state ELIC structure.
In summary, cumulative evidence indicates the existence of
different binding sites in pLGICs for general anesthetics. One
site is located in the upper part of the transmembrane domain
in an intrasubunit pocket between the M1- and M3-helix of a
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single subunit, which corresponds to the binding site for propo-
fol and desflurane (Fig. 8, green sphere) (18). A second trans-
membrane site is located at the subunit interface formed
between the M1-helix of one subunit and the M3-helix of a
neighboring subunit (Fig. 8, yellow sphere). This site corre-
sponds to the binding site for alcohols, certain general anesthet-
ics, and ivermectin (14). Our study unveils a novel transmem-
brane anesthetic binding site located farther down the
transmembrane domain at an interface formed between the
M1- and M4-helix of one subunit and the M3-helix of a neigh-
boring subunit (Fig. 8, magenta sphere (IS)). In addition, we
provide the first experimental evidence that certain anesthetics,
such as chloroform and bromoform, can bind in the hydropho-
bic portion of the channel pore (Fig. 8, magenta sphere (PS)).
Together, these studies substantiate the view of multisite allos-
teric modulation in the family of pentameric ligand-gated ion
channels.
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